Jazz Pharmaceuticals plc — Director's Dealing 2016

Feb 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-02-25

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-25	Ordinary Shares	A	31000.0	$0.0	Acquired	312896	Direct
2016-02-26	Ordinary Shares	F	2607.0	$125.0	Disposed	310289	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-25	Incentive Stock Option (right to buy)	$123.36	A	811.0	Acquired	2026-02-24	Ordinary Shares (811)	Direct
2016-02-25	Non-Qualified Stock Option (right to buy)	$123.36	A	76689.0	Acquired	2026-02-24	Ordinary Shares (76689)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in four equal annual installments on the anniversary of the grant date, February 25, 2016.

F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F3: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.